<DOC>
	<DOCNO>NCT00677833</DOCNO>
	<brief_summary>The primary objective confirm hypothesis azithromycin use combination chloroquine non-inferior artemether- Lumefantrine treatment symptomatic , uncomplicated malaria due P. falciparum child African country .</brief_summary>
	<brief_title>Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated P. Falciparum Malaria In Children In Africa</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<criteria>Girls boys ≥5 year ≤12 year ( Cohort 1 ) ; ≥6 ≤59 month age ( Cohort 2 ) uncomplicated , symptomatic malaria indicate presence following : Blood smear positive monoinfection P. falciparum asexual parasitemia 1000 100,000 parasites/µL ; Documented fever ( 38.0°C/100.4°F rectal tympanic ; 37.2°C/99.0°F axillary 37.5°C/99.5°F oral ) history fever ( report legally acceptable representative ) within prior 24 hour ; Appropriate outpatient treatment ; Blood glucose ≥60 mg/dL ; Hemoglobin ≥6 g/dl hematocrit ≥18 % without sign anemiainduced Congestive Heart Failure ( CHF ) ; Negative urine pregnancy test females ≥10 year age ( child bear potential ) Peripheral blood smear positive mixed infection multiple Plasmodium spp . Severe complicate malaria include subject follow : Impaired consciousness ( eg , obtundation , unarousable coma ) , seizures abnormal neurologic exam suggestive severe complicate malaria ; Known hemoglobinuria ; Jaundice ; Respiratory distress ; Persistent vomiting ; Gross hematuria , report subject 's legally acceptable representative ; Recent history convulsion ; Inability drink breastfeed ; Unable sit stand appropriate age ; Known pregnancy breastfeed positive urine pregnancy test ( female ≥10 year age child bear potential ) ; History allergy hypersensitivity azithromycin , macrolide , chloroquine , artemether , artemisinin derivative , lumefantrine ; Any contraindication study drug include AZ , CQ AL ; History treatment antimalarial drug ( halofantrine , chloroquine , quinine , mefloquine , Malarone , SP , artemisinin compound ) antibacterial know antimalarial activity ( macrolides , doxycycline , clindamycin ) within 2 week prior enrollment subject ( and/or mother subject breastfed ) study ; Known suspect cardiovascular , hepatic renal abnormality opinion investigator would place subject increase risk participate study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>P. Falciparum Malaria</keyword>
	<keyword>drug treatment</keyword>
	<keyword>clinical trial</keyword>
</DOC>